Volufiline’s 2.2% breast-volume gain lacked statistical significance

By Amara Osei

In a 56-day study of 28 women, Sederma found that a cream containing Volufiline increased average breast volume by 2.2%, a change that did not reach statistical significance.

That modest result sits beneath a larger promise on social media: users liken Volufiline to natural filler in a bottle, with restored volume and a younger appearance without needles, lasers or a scalpel.

Men are dabbing the topical onto undereyes, smile lines, cheeks and lips. One X user claimed that after two weeks, the skin looked as though it had genuinely received a facelift.

What Volufiline contains

Volufiline is a trademarked cosmetic ingredient made with Anemarrhena asphodeloides root extract, a source of sarsasapogenin, and hydrogenated polyisobutene, an emollient that softens and smooths skin.

Kseniya Kobets, MD, director of cosmetic dermatology at Montefiore Einstein Advanced Care, explained the proposed mechanism: “The theory is that sarsasapogenin encourages fat cells to develop and store more lipids, making them fuller.” The intended target is the volume loss that accompanies ageing.

The limits of the 28-woman study

Sederma, the French company that manufactures Volufiline, applied the cream to one breast in each of 28 women for 56 days. The average volume of the treated breast rose 2.2%, but the result was not statistically significant.

The comparator was an untreated breast, not the same cream without Volufiline. The design therefore cannot determine whether Volufiline or another component of the formula produced the increase. Results from female breasts also cannot be extrapolated directly to a man’s face.

The study does not provide robust clinical support for anti-ageing or facial-volume claims. Visually persuasive before-and-after photographs on social media cannot fill that evidential gap. Any claim that the topical rebuilds facial fat moves beyond the study’s findings.

Surface plumping versus structural volume

Hydration can soften fine lines, emollients can smooth the skin surface, and changes in light reflection can make skin appear more luminous. Lighting and camera angles can also improve the appearance of after photographs.

Kobets drew the practical distinction: hydrated, plump-looking skin does not demonstrate the rebuilding of underlying fat. She said some improvement likely comes from the moisturizing formula rather than from new fat beneath the skin.

Alexandra Bowles, DO, a board-certified dermatologist at MONA Dermatology, set a narrower expectation: “Volufiline is designed to support volume in the skin, and some people may notice slightly plumper, fuller-looking skin over time.”

Injectable filler, Bowles said, adds volume and structure immediately and can reshape the tear trough, lips and jawline. A topical works at the surface and builds gradually, so it cannot replicate those changes. The two categories should not be presented as equivalent outcomes.

What does this change for product development and buying?

It moves the burden onto claim design and substantiation. A Volufiline-containing cream may improve the look and feel of skin, but available data do not establish that it restores facial fat or matches an injectable result.

This study cannot isolate the ingredient’s contribution from the cream base, and buyers should resist structural-volume promises unsupported by a controlled facial trial. Formulation decisions should therefore separate surface-conditioning claims from deeper volume claims.

Neither Kobets nor Bowles rules out patient trials, but both attach conditions. Bowles considers Volufiline worth trying with realistic expectations and considers it overhyped as an alternative to filler. Kobets does not rule out a trial either, while warning against expecting the restoration of facial fat.

For people with chronic conditions such as eczema or rosacea, and for acne-prone skin, Kobets advises caution. Patch testing comes first; users should stop if the skin stings or burns.

Procurement should start with reputable brands that publish clear ingredient lists and make modest claims about gradual improvements in skin appearance and feel. Bowles advises avoiding products that promise instant results, offer vague ingredient lists or come from unverified sellers. Kobets warns against experimenting with raw ingredients or assuming that a higher percentage works better.

The next data point

More rigorous research must test the volume-enhancing claims on facial skin and separate Volufiline from the finished cream. The next data point to watch is controlled facial research comparing a Volufiline-containing cream with the same base without Volufiline; no follow-up study date has been specified.